Revenue: As of FY2025 Q1, the actual value is USD 62.87 K.EPS: As of FY2025 Q1, the actual value is USD -1.11.<h3>Biotechnology Segment</h3><ul><li>Net Loss from Operations: The biotechnology segment reported a net loss from operations of $4,014,702 for the three months ended March 31, 2025.</li></ul><h3>Technology Segment</h3><ul><li>Sales: The technology segment generated sales of $62,874 for the three months ended March 31, 2025.</li><li>Cost of Goods Sold: The cost of goods sold for the technology segment was $45,156 for the same period.</li><li>Net Loss from Operations: The technology segment reported a net loss from operations of $42,282 for the three months ended March 31, 2025.</li></ul><h3>Consolidated Financial Metrics</h3><ul><li>Total Operating Expenses: Total operating expenses for the company were $4,074,702 for the three months ended March 31, 2025, compared to $2,922,383 for the same period in 2024.</li><li>Net Loss from Operations: The consolidated net loss from operations was $4,056,984 for the three months ended March 31, 2025, compared to $2,922,383 for the same period in 2024.</li><li>Interest Expense: Interest expense decreased to $71,491 for the three months ended March 31, 2025, from $200,505 for the same period in 2024.</li><li>Change in Fair Value of Derivative Liabilities: The change in fair value of derivative liabilities resulted in a gain of $596,120 for the three months ended March 31, 2025, compared to a gain of $34,875 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was - $2,366,167 for the three months ended March 31, 2025.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $6,101,650 for the three months ended March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Biotechnology Segment: The company plans to continue developing its biotechnology product pipeline, focusing on innovative cell therapy technologies for cancer and other diseases.</li><li>Technology Segment: The company aims to enhance operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools.</li><li>Overall Strategy: The company expects to increase operating expenses to support business growth and anticipates raising additional capital through equity transactions to improve liquidity and execute its operating strategy.</li></ul>

Coeptis Therapeutics - CW25 | 10-Q: FY2025 Q1 Revenue: USD 62.87 K